Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Thyroid hormone receptors in breast cancer- prognostic and predictive implications

FY 2015-16

Summary
Survival of breast cancer patients has improved in the past 20 years due to advancements in hormonal and anti-HER2 directed therapies. These benefits accrue to women with ER/PR+ve or HER2+ve cancers, but not the 20% with triple negative disease. However, it is possible that other hormone receptors (e.g. thyroid receptors) and their associated endocrine pathways may stimulate cancer growth, in the absence or presence of ER/PR and HER2. If so, these receptors may have prognostic, predictive and even therapeutic potential. One thyroid hormone receptor (THRa2) is of particular interest, because its expression was associated with improved survival in our study of 130 women with largely ER+ve breast cancer and 158 women with triple negative disease. I will validate these findings in the Henrietta Banting Breast Centre database, which consists of archived tumors and corresponding clinical data with at least 15 year follow-up for 1601 women treated between 1987 and 1997 at Women’s College Hospital. The ability of THRa2 to predict patients' response to a standard hormone therapy (tamoxifen) will be studied in a relevant clinical trial (the NCIC CTG MA.12 trial) using archived tissue. These results may help women with breast cancer weigh the risks and benefits of hormone therapy, particularly when considering extended treatment courses.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
349854
Name
Jerzak Katarzyna J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Thyroid hormone receptors in breast cancer- prognostic and predictive implications
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Predictive Biomarker; Prognostic Biomarker; Retrospective Analysis Of A Clinical Trial; Retrospective Database; Tamoxifen; Thyroid Hormone Receptor
Abstract
Survival of breast cancer patients has improved in the past 20 years due to advancements in hormonal and anti-HER2 directed therapies. These benefits accrue to women with ER/PR+ve or HER2+ve cancers, but not the 20% with triple negative disease. However, it is possible that other hormone receptors (e.g. thyroid receptors) and their associated endocrine pathways may stimulate cancer growth, in the absence or presence of ER/PR and HER2. If so, these receptors may have prognostic, predictive and even therapeutic potential. One thyroid hormone receptor (THRa2) is of particular interest, because its expression was associated with improved survival in our study of 130 women with largely ER+ve breast cancer and 158 women with triple negative disease. I will validate these findings in the Henrietta Banting Breast Centre database, which consists of archived tumors and corresponding clinical data with at least 15 year follow-up for 1601 women treated between 1987 and 1997 at Women’s College Hospital. The ability of THRa2 to predict patients' response to a standard hormone therapy (tamoxifen) will be studied in a relevant clinical trial (the NCIC CTG MA.12 trial) using archived tissue. These results may help women with breast cancer weigh the risks and benefits of hormone therapy, particularly when considering extended treatment courses.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jerzak, Katarzyna J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~